Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Immunovaccine begins Phase Ib/II of HPV-related cancer vaccine DPX-E7

In April, Immunovaccine Inc. (TSX:IMV; OTCQX:IMMVF) said that the Dana-Farber Cancer Institute (Boston, Mass.) began a Phase

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE